Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis
Primary Purpose
Adenoviral Keratoconjunctivitis
Status
Completed
Phase
Phase 4
Locations
Tunisia
Study Type
Interventional
Intervention
FLUCON®
Cyclosporine A eye drops 0.5%
Sponsored by
About this trial
This is an interventional treatment trial for Adenoviral Keratoconjunctivitis focused on measuring adenoviral keratoconjunctivitis, corticosteroid, cyclosporine, cornea, subepithelial infiltrates
Eligibility Criteria
Inclusion Criteria:
- patients having subepithelial infiltrates following epidemic keratoconjunctivites persisting for 14 days or more
Exclusion Criteria:
- a past history of glaucoma or other anterior or posterior segment disease or surgery
- a chronic use of topical or systemic medications
- pregnancy,
- contact lens wearers,
- patients who couldn't attend at least two regimen visits
Sites / Locations
- Military Hospital of Tunis
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Fluorometholone group
Cyclosporine A group
Arm Description
This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
Outcomes
Primary Outcome Measures
Mean change from baseline in subepithelial infiltrates number
The subepithelial infiltrates were counted at baseline and at each control visit.The mean change was then calculated between each two visits. Treatment was considrerd efficient if the subepithelial infiltrates decreased half the baseline number or completely disappeared.
Mean change from baseline in Schirmer type 1 value
The Schirmer value was assessed without local anesthesia. Treatment was considered efficient with a good tolerance when the schirmer type 1 was superior than 5ml/5min.
Secondary Outcome Measures
Mean change from baseline in best corrected visual acuity
A gain of two snellen lines from baseline was considered a mark of treatment efficiency.
Mean change from baseline in spheric equivalent
Spheric equivalent was calculated using an automatic refraction. An increase from baseline of 0.25 dioptries was considered a mark of treatment efficiency.
Mean change from baseline in clinical score
These subjective variables : (1) photophobia; (2) Foreign body sensation ; (3) Visual blurring ; (4) tearing and (5) ocular pain were evaluated according to their severity (0 indicated no ; 1, mild ; and 2, severe). The sum of these variables was calculated for each visit and called clinical score.
Overall satisfaction with treatment subjective evaluation: scale
For subjective evaluation of the treatment, patients were asked to evaluate in the seventh month their overall satisfaction with treatment on a scale of 0-10. 0 means no satisfaction with the treatment and 10 means an excellent satisfaction with the treatment.
Number of participants with burning sensation upon eyedrops instillation
Burning sensation upon eyedrops instillation was considered as a treatment intolerance mark.
Mean change from baseline in intraocular pressure
Intraocular pressure was measured with with non contact tonometers. An increase of 6 mmHg from baseline value was defined as a steroid-induced glaucoma.
Number of participants with appearance of lens opacification and corneal ulcer or superinfection
Lens opacification and corneal ulcer or superinfection were considered as a mark of corticosteroid intolerance.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04376970
Brief Title
Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis
Official Title
Treatment of Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: Corticosteroids Versus Cyclosporine Eyedrops: A Randomized Double-blind Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
April 1, 2017 (Actual)
Primary Completion Date
April 1, 2019 (Actual)
Study Completion Date
April 1, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Military Hospital of Tunis
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Purpose:
To compare efficiency and tolerance between topical 0.5% cyclosporine A and fluorometholone in patients with subepithelial corneal infiltrates (SEIs).
Methods :
A prospective double-blind randomized study was conducted involving 72 eyes, 38 treated with topical fluorometholone and 34 eyes treated with cyclosporine A 0.5% eyedrops, having SEIs. Treatment was considered successful if there was reduction of SEIs and improvement in visual acuity (two snellen lines). Tolerance was mainly evaluated by Schirmer test, conjunctival hyperemia and burning sensation upon eyedrops instillation.
Detailed Description
This study was performed on the 72 eyes of 51 patients who were referred to our clinics for epidemic keratoconjunctivitis (EKC).Diagnosis of EKC was based on the constellation of clinical features. The investigators conducted a double-blind randomized prospective parallel trial involving : 38 patients treated with topical fluorometholone and 34 eyes treated with cyclosporine A 0.5% eye drops. Cyclosporine A eye drops were prepared in Ricin oil by the pharmacy of Tunis Military Hospital. The sample size was measured by our research department, to obtain a conclusion of non-inferiority of cyclosporine A compared to fluorometholone in the chronic phase of EKC.
Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called " wash-out ". Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen.The regimen was the same for both treatments in order to preserve the double-blind characteristic : 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
Patients were examined on admission to the study and one month , three months, six months and seven months after the onset of treatment. The investigators followed a double-masked fashion in all the phases of the study.
Information gathered in M0 included basic demographic information (age and sex), medical and ophtalmological history, involved eye(s) and duration of symptoms in the acute episode. The investigators evaluated and recorded the interval of time between the onset of the infection and the beginning of the trial and called it " pretherapeutic period ". At each visit, SEIs were photo-documented, best corrected visual acuity (converted to mean logarithm of the minimum angle of resolution), spheric equivalent, SEIs number, intraocular pressure (with non contact tonometers), break-up time and Schimer test type 1 and cup/disc score were recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adenoviral Keratoconjunctivitis
Keywords
adenoviral keratoconjunctivitis, corticosteroid, cyclosporine, cornea, subepithelial infiltrates
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The allocation sequence of the treatment was generated by chance and concealed until all the study was over and all outcomes were assessed. Consecutive patients with subepithelial infiltrates were randomly allocated to one of the two groups by a parallel assignment (1:1).
Allocation
Randomized
Enrollment
51 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fluorometholone group
Arm Type
Active Comparator
Arm Description
This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
Arm Title
Cyclosporine A group
Arm Type
Active Comparator
Arm Description
This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
Intervention Type
Drug
Intervention Name(s)
FLUCON®
Other Intervention Name(s)
Fluorometholone
Intervention Description
The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called " wash-out ". Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen.
Intervention Type
Drug
Intervention Name(s)
Cyclosporine A eye drops 0.5%
Other Intervention Name(s)
CsA
Intervention Description
The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
Primary Outcome Measure Information:
Title
Mean change from baseline in subepithelial infiltrates number
Description
The subepithelial infiltrates were counted at baseline and at each control visit.The mean change was then calculated between each two visits. Treatment was considrerd efficient if the subepithelial infiltrates decreased half the baseline number or completely disappeared.
Time Frame
day 0, Month 1, Month 3, Month 6, Month 7
Title
Mean change from baseline in Schirmer type 1 value
Description
The Schirmer value was assessed without local anesthesia. Treatment was considered efficient with a good tolerance when the schirmer type 1 was superior than 5ml/5min.
Time Frame
day 0, Month 1, Month 3, Month 6, Month 7
Secondary Outcome Measure Information:
Title
Mean change from baseline in best corrected visual acuity
Description
A gain of two snellen lines from baseline was considered a mark of treatment efficiency.
Time Frame
day 0, Month 1, Month 3, Month 6
Title
Mean change from baseline in spheric equivalent
Description
Spheric equivalent was calculated using an automatic refraction. An increase from baseline of 0.25 dioptries was considered a mark of treatment efficiency.
Time Frame
day 0, Month 6
Title
Mean change from baseline in clinical score
Description
These subjective variables : (1) photophobia; (2) Foreign body sensation ; (3) Visual blurring ; (4) tearing and (5) ocular pain were evaluated according to their severity (0 indicated no ; 1, mild ; and 2, severe). The sum of these variables was calculated for each visit and called clinical score.
Time Frame
day 0, Month 1, Month 3, Month 6
Title
Overall satisfaction with treatment subjective evaluation: scale
Description
For subjective evaluation of the treatment, patients were asked to evaluate in the seventh month their overall satisfaction with treatment on a scale of 0-10. 0 means no satisfaction with the treatment and 10 means an excellent satisfaction with the treatment.
Time Frame
Month 7
Title
Number of participants with burning sensation upon eyedrops instillation
Description
Burning sensation upon eyedrops instillation was considered as a treatment intolerance mark.
Time Frame
day 0, Month 1, Month 3, Month 6
Title
Mean change from baseline in intraocular pressure
Description
Intraocular pressure was measured with with non contact tonometers. An increase of 6 mmHg from baseline value was defined as a steroid-induced glaucoma.
Time Frame
day 0, Month 1, Month 3, Month 6
Title
Number of participants with appearance of lens opacification and corneal ulcer or superinfection
Description
Lens opacification and corneal ulcer or superinfection were considered as a mark of corticosteroid intolerance.
Time Frame
up to six months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
9 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients having subepithelial infiltrates following epidemic keratoconjunctivites persisting for 14 days or more
Exclusion Criteria:
a past history of glaucoma or other anterior or posterior segment disease or surgery
a chronic use of topical or systemic medications
pregnancy,
contact lens wearers,
patients who couldn't attend at least two regimen visits
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Afef Maalej
Organizational Affiliation
Military Hospital of Tunis
Official's Role
Study Director
Facility Information:
Facility Name
Military Hospital of Tunis
City
Tunis
State/Province
Illinois
Country
Tunisia
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
20458220
Citation
Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010 Jun;29(6):638-40. doi: 10.1097/ICO.0b013e3181c33034.
Results Reference
background
PubMed Identifier
26489119
Citation
Maychuk DY, Vasil'eva OA, Russu LI, Mezentseva MV. [Clinical and immunological comparisons of therapeutic regimens for corneal infiltrates secondary to adenoviral keratoconjunctivitis]. Vestn Oftalmol. 2015 Jul-Aug;131(4):49-55. doi: 10.17116/oftalma2015131449-55. Russian.
Results Reference
result
PubMed Identifier
11130165
Citation
Reinhard T, Godehardt E, Pfahl HG, Sundmacher R. [Local cyclosporin A in nummuli after keratoconjunctivitis epidemica. A pilot study]. Ophthalmologe. 2000 Nov;97(11):764-8. doi: 10.1007/s003470070025. German.
Results Reference
result
PubMed Identifier
25043311
Citation
Aydin Kurna S, Altun A, Oflaz A, Karatay Arsan A. Evaluation of the impact of persistent subepithelial corneal infiltrations on the visual performance and corneal optical quality after epidemic keratoconjunctivitis. Acta Ophthalmol. 2015 Jun;93(4):377-82. doi: 10.1111/aos.12496. Epub 2014 Jul 6.
Results Reference
result
PubMed Identifier
33201059
Citation
Gouider D, Khallouli A, Maalej A, Yousfi MA, Ksiaa I, Bouguerra C, Ajili F, Khairallah M. Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study. Cornea. 2021 Jun 1;40(6):726-732. doi: 10.1097/ICO.0000000000002589.
Results Reference
derived
Learn more about this trial
Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis
We'll reach out to this number within 24 hrs